Aura Biosciences Inc (AURA)
NASDAQ:AURA
AURA Stock Chart & Stats
$6.77
-$0.11(-1.36%)
At close: 4:00 PM EST
$6.77
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.35 - $7.48
Previous CloseN/A
Volume82.15K
Average Volume (3M)269.06K
Market Cap
$434.30M
Enterprise Value$392.16M
Total Cash (Recent Filing)$144.24M
Total Debt (Recent Filing)$17.38M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding64,150,470
10 Day Avg. Volume261,712
30 Day Avg. Volume269,062
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$22.50Price Target Upside232.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentAccelerated enrollment in the late-stage CoMpass trial could produce an earlier-than-expected topline readout, shortening the path to pivotal clinical data.
Drug Formulation And CommercializationA new formulation that remains stable without cold-chain requirements simplifies in-office administration and supports broader adoption across urology and other solid tumor settings.
Regulatory SupportFast Track and Orphan Drug designations provide regulatory incentives that can facilitate expedited review and potential approval if clinical outcomes are supportive.
Bears Say
Cash RunwayAnnualized cash burn implies a limited cash runway that may create financing needs for the company.
Financing Dilution RiskNeed to secure additional capital to fund ongoing development could lead to shareholder dilution and pressure on the stock.
Program Execution RiskFunding constraints could force reprioritization of programs or slow trial activities, increasing the risk of delays in key clinical milestones.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.34 and its highest was $7.48 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $434.30M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is May 07, 2026 which is in 27 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Mar 30, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.428 by $0.088.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 64,150,470 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.428. Following the earnings report the stock price went down -1.116%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (232.35% Upside)
$22.50 (232.35% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $618.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.02%
12-Months-Change
Fundamentals
Return on Equity
-71.25%
Trailing 12-Months
Asset Growth
75.33%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
AURA Stock 12 Month Forecast
Average Price Target
$22.50
▲(232.35% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.05% Insiders
8.32% Mutual Funds
54.83% Other Institutional Investors
26.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---